Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

NCT ID: NCT04298515

Last Updated: 2020-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-02

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Insulin Resistance Obesity Nesfatin-1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 Diabetes group

In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.

Group Type OTHER

Nesfatin-1

Intervention Type DIAGNOSTIC_TEST

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Insulin resistance group

In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.

Group Type OTHER

Nesfatin-1

Intervention Type DIAGNOSTIC_TEST

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Obesity group

In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.

Group Type OTHER

Nesfatin-1

Intervention Type DIAGNOSTIC_TEST

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nesfatin-1

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes
* Insulin resistance
* Obesity disease

Exclusion Criteria

* Pediatric individuals
* All patients who are hospitalized,
* Liver disease
* Cancer patients
* Disease related to the gastrointestinal tract
* Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
* Neurological disease
Minimum Eligible Age

19 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul Medeniyet University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gülin Öztürk Özkan

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gülin Öztürk Özkan, Assis Prof

Role: STUDY_CHAIR

İstanbul Medeniyet University

Kadir Kayataş, associate professor

Role: STUDY_DIRECTOR

Haydarpaşa Numune Education and Research Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haydarpaşa Numune Education and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gülin Öztürk Özkan, Assis Prof

Role: CONTACT

02162803333

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gülin Öztürk Özkan, Assis Prof

Role: primary

02162803333

References

Explore related publications, articles, or registry entries linked to this study.

Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017 Jan;232(1):R45-R65. doi: 10.1530/JOE-16-0361. Epub 2016 Oct 17.

Reference Type BACKGROUND
PMID: 27754932 (View on PubMed)

Mirzaei K, Hossein-nezhad A, Keshavarz SA, Koohdani F, Eshraghian MR, Saboor-Yaraghi AA, Hosseini S, Chamari M, Zareei M, Djalali M. Association of nesfatin-1 level with body composition, dietary intake and resting metabolic rate in obese and morbid obese subjects. Diabetes Metab Syndr. 2015 Oct-Dec;9(4):292-8. doi: 10.1016/j.dsx.2014.04.010. Epub 2014 May 25.

Reference Type BACKGROUND
PMID: 25470645 (View on PubMed)

Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010 Jan 8;159(1-3):72-7. doi: 10.1016/j.regpep.2009.11.003.

Reference Type RESULT
PMID: 19896982 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HNEAH-KAEK 2019/100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.